Pfizer Highlights Encouraging Data for RSV Vaccine

The respiratory syncytial virus (RSV) vaccine Abrysvo, which Pfizer developed, has shown promising topline findings from a crucial late-stage research in immunocompromised individuals who are at a higher risk for suffering severe RSV-associated lower respiratory tract disease (LRTD).

In the substudy B section of the pivotal Phase III MONeT study, arysvo was shown to be tolerated favourably. Pfizer stated that a single 120 µg dosage of the vaccine produced “strong neutralizing” reactions against RSV-A and RSV-B, whereas substudy B assessed two 120 µg doses of Abrysvo.

senior vice president and CSO, Vaccine Research and Development, Annaliesa Anderson, PhD stated: “Immunocompromised adults, such as patients with cancer or autoimmune disorders, have a substantially increased risk of experiencing severe complications from RSV, yet there are currently no vaccines approved for those aged 18 to 59 in the U.S.”

RSV is a respiratory virus that is extremely infectious and frequently manifests as a regular cold. On the other hand, serious sickness and problems can be more likely among young children, the elderly, and people with certain underlying chronic diseases.